During the first administration of a monoclonal antibody, how should infusion reactions be assessed?

• A. Monitor vitals every 60 minutes only.
• B. Monitor vitals continuously without stopping if mild symptoms occur.
• C. Monitor vitals every 15–30 minutes, assess for facial flushing, wheeze, hypotension, and notify clinician if reactions occur.
• D. No monitoring is needed unless symptoms appear.

Answer: (C)

The main idea is safety monitoring and early recognition of infusion reactions during the first monoclonal antibody administration. Infusion reactions can develop quickly and progress, so frequent checks and attention to specific symptoms are essential for prompt intervention.

Monitoring vitals every 15–30 minutes during the infusion and for a period after, while actively looking for signs such as facial flushing, wheeze, and hypotension, allows rapid detection and escalation if a reaction occurs. Notifying the clinician immediately enables actions like pausing or stopping the infusion and starting appropriate treatment to prevent escalation.

Other approaches are less safe: monitoring every 60 minutes may miss early changes; continuous monitoring without stopping for mild symptoms delays management; and not monitoring at all unless symptoms appear ignores potential early or asymptomatic reactions.